Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
"A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events"	McMaster University	Ongoing	Vaxigrip	3	version 2	King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), King Fahad Medical City (Riyadh), Madinah Cardiac Center
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	King Faisal Specialist Hospital and Research Center (Riyadh)
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	King Faisal Specialist Hospital and Research Center (Riyadh)
Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML.	King Fahad Medical City	Ongoing	Vidaza	2	Version 1.1	King Fahad Medical City (Riyadh)
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Bristol-Myers Squibb	Terminated	NIVOLUMAB/IPILIMUMAb	3	CA209-227	King Faisal Specialist Hospital and Research Center (Riyadh)
Asia and Latin America Fracture Observational Study	Eli Lilly	Ongoing	Forteo (teriparatide)	4	B3D-MC-B02	King Fahad Medical City (Riyadh), Al-Noor Specialist Hospital, King Fahad Hospital (Jeddah), Sabia General Hospital, King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive"	Bristol-Myers Squibb	Terminated	Abatacept	3b	IM101550	King Fahad Medical City (Riyadh)
An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)	Astellas	Rejected	Mirabegron	3	178-CL-206A	N\A
"randomised, multicentre, double-blind, placebo-controlledstudy of ambrisentan in subjects with inoperable chronicthromboembolic pulmonary hypertension (CTEPH)"	GSK	Terminated	Ambrisentan 5 mg	3	AMB115811	N\A
Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE)	KAIMRC	Rejected	Dexmedetomidine	3	RC11/084	N\A